Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Dementia and mortality rates rise inexorably with age and consequently interact. However, because of the major logistical difficulties in accounting for both outcomes in a defined population, very little work has examined how risk factors and biomarkers for incident dementia are influenced by competing mortality. The objective of this study was to examine long-term associations between amyloid PET, APOE ɛ4, sex, education and cardiovascular/metabolic conditions, and hazard and absolute risk of dementia and mortality in individuals without dementia at enrolment. Participants were enrolled in the Mayo Clinic Study of Aging, a population-based study of cognitive ageing in Olmsted County, MN, USA. All were without dementia and were age 55–92 years at enrolment and were followed longitudinally. Predictor variables were amyloid PET, APOE ɛ4 status, sex, education, cardiovascular/metabolic conditions and age. The main outcomes were incident dementia and mortality. Multivariable, multi-state models were used to estimate mortality and incident dementia rates and absolute risk of dementia and mortality by predictor variable group. Of the 4984 participants in the study, 4336 (87%) were cognitively unimpaired and 648 (13%) had mild cognitive impairment at enrolment. The median age at enrolment was 75 years; 2463 (49%) were women. The median follow-up time was 9.4 years (7.5 years after PET). High versus normal amyloid (hazard ratio 2.11, 95% confidence interval 1.43–2.79), APOE ɛ4 (women: hazard ratio 2.24, 95% confidence interval 1.80–2.77; men: hazard ratio 1.37, 95% confidence interval 1.09–1.71), older age and two additional cardiovascular/metabolic conditions (hazard ratio 1.37, 95% confidence interval 1.22–1.53) were associated with the increased hazard of dementia (all P < 0.001). Among APOE ɛ4 carriers with elevated amyloid, remaining lifetime risk of dementia at age 65 years was greater in women [74% (95% confidence interval 65–84%) high and 58% (95% confidence interval 52–65%) moderate amyloid], than men [62% (95% confidence interval 52–73%) high and 44% (95% confidence interval 35–53%) moderate amyloid]. Overall, the hazard and absolute risk of dementia varied considerably by predictor group. The absolute risk of dementia associated with predictors characteristic of Alzheimer’s disease was greater in women than men while at the same time the combination of APOE ɛ4 non-carrier with normal amyloid was more protective in women than men. This set of findings may be attributed in part to different biological effects and in part to lower mortality rates in women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“target fibrillar forms of β-amyloid can effectively decrease amyloid load.(84,85) While our data are observational and therefore cannot prove that removing amyloid would reduce incidence rates or absolute risk of dementia, the results show that those with higher amyloid progress to dementia at faster rates and have si…”
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348 · cited 1×
“The continuous range of amyloid PET values was divided into normal, moderately elevated (referred to as moderate) and highly elevated (referred to as high) ranges on the Centiloid scale.(35,36) The cut point separating normal and moderate amyloid was Centiloid 22 [standardized uptake value ratio (SUVR) 1.”
Karikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316
Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differences
Mielke, M., Vemuri, P., & Rocca, W. (2014) · Clinical Epidemiology · doi:10.2147/clep.s37929 · Cited by 1,021
Self-citationDefining imaging biomarker cut points for brain aging and Alzheimer's disease
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Gunter, J. L., Senjem, M. L., Jones, D. T., Kantarci, K., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.005 · Cited by 931
Self-citationSex modifies the APOE ‐related risk of developing Alzheimer disease
Altmann, A., Tian, L., Henderson, V. W., Greicius, M. D., & Alzheimer's Disease Neuroimaging Initiative Investigators (2014) · Annals of Neurology · doi:10.1002/ana.24135 · Cited by 891 · cited 2×
“This set of findings implies different biological effects in women versus men.(15,27,71,74,75) We also found a sex difference in the relationship between amyloid PET level and the hazard of incident dementia.”
Understanding the impact of sex and gender in Alzheimer’s disease: A call to action
Nebel, R. A., Aggarwal, N. T., Barnes, L. L., Gallagher, A., Goldstein, J. M., Kantarci, K., Mallampalli, M. P., Mormino, E. C., Scott, L., Yu, W. H., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.04.008 · Cited by 839
Self-citationLongitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22248 · Cited by 833
Hansson, O., Seibyl, J., Stomrud, E., Zetterberg, H., Trojanowski, J. Q., Bittner, T., Lifke, V., Corradini, V., Eichenlaub, U., Batrla, R., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.010 · Cited by 808 · cited 1×
“Alzheimer’s disease is defined by the presence of both β-amyloid plaques and tau neurofibrillary tangles,(4) which can be ascertained in vivo by PET imaging or biofluid biomarkers.(5)”
Alzheimer's disease drug development pipeline: 2019
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.008 · Cited by 762
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761
Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis
Neu, S. C., Pa, J., Kukull, W., Beekly, D., Kuzma, A., Gangadharan, P., Wang, L.-S., Romero, K., Arneric, S. P., Redolfi, A., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2188 · Cited by 674
Vermunt, L., Sikkes, S. A. M., van den Hout, A., Handels, R., Bos, I., van der Flier, W. M., Kern, S., Ousset, P., Maruff, P., Skoog, I., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.04.001 · Cited by 570
Longitudinal Modeling of Age-Related Memory Decline and the APOE ε4 Effect
Caselli, R. J., Dueck, A. C., Osborne, D., Sabbagh, M. N., Connor, D. J., Ahern, G. L., Baxter, L. C., Rapcsak, S. Z., Shi, J., Woodruff, B. K., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809437 · Cited by 528
Seshadri, S., Wolf, P. A., Beiser, A., Au, R., McNulty, K., White, R., & D'Agostino, R. B. (1997) · Neurology · doi:10.1212/wnl.49.6.1498 · Cited by 489
Age-specific incidence rates of Alzheimer’s disease: The Baltimore Longitudinal Study of Aging
Kawas, C., Gray, S., Brookmeyer, R., Fozard, J., & Zonderman, A. (2000) · Neurology · doi:10.1212/wnl.54.11.2072 · Cited by 472
Incidence and Risk of Dementia: The Rotterdam study
Ott, A., Breteler, M. M. B., Harskamp, F. V., Stijnen, T., & Hofman, A. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009489 · Cited by 455
Donohue, M. C., Sperling, R. A., Petersen, R., Sun, C.-K., Weiner, M. W., Aisen, P. S., & Initiative, F. T. A. D. N. (2017) · JAMA · doi:10.1001/jama.2017.6669 · Cited by 452
Self-citationBrain β-amyloid load approaches a plateau
Jack, C. R., Wiste, H. J., Lesnick, T. G., Weigand, S. D., Knopman, D. S., Vemuri, P., Pankratz, V. S., Senjem, M. L., Gunter, J. L., Mielke, M. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182840bbe · Cited by 406
Self-citationAPOE -ε4 count predicts age when prevalence of AD increases, then declines: The Cache County Study
Breitner, J. C. S., Wyse, B. W., Anthony, J. C., Welsh-Bohmer, K. A., Steffens, D. C., Norton, M. C., Tschanz, J. T., Plassman, B. L., Meyer, M. R., Skoog, I., et al. (1999) · Neurology · doi:10.1212/wnl.53.2.321 · Cited by 397
Sex differences in the association between AD biomarkers and cognitive decline
Initiative, F. T. A. N., Koran, M. E. I., Wagener, M., & Hohman, T. J. (2017) · Brain Imaging and Behavior · doi:10.1007/s11682-016-9523-8 · Cited by 339
Multiple pathologies are common and related to dementia in the oldest-old: The 90+ Study
Kawas, C. H., Kim, R. C., Sonnen, J. A., Bullain, S. S., Trieu, T., & Corrada, M. M. (2015) · Neurology · doi:10.1212/wnl.0000000000001831 · Cited by 303
Buckley, R. F., Mormino, E. C., Amariglio, R. E., Properzi, M. J., Rabin, J. S., Lim, Y. Y., Papp, K. V., Jacobs, H. I. L., Burnham, S., Hanseeuw, B. J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.04.010 · Cited by 276 · cited 2×
“This set of findings implies different biological effects in women versus men.(15,27,71,74,75) We also found a sex difference in the relationship between amyloid PET level and the hazard of incident dementia.”
Nelson, P. T., Abner, E. L., Schmitt, F. A., Kryscio, R. J., Jicha, G. A., Smith, C. D., Davis, D. G., Poduska, J. W., Patel, E., Mendiondo, M. S., et al. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00244.x · Cited by 239
Roberts, R. O., Aakre, J. A., Kremers, W. K., Vassilaki, M., Knopman, D. S., Mielke, M. M., Alhurani, R., Geda, Y. E., Machulda, M. M., Coloma, P., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0629 · Cited by 223
Self-citationRowe, C. C., Bourgeat, P., Ellis, K. A., Brown, B., Lim, Y. Y., Mulligan, R., Jones, G., Maruff, P., Woodward, M., Price, R., et al. (2013) · Annals of Neurology · doi:10.1002/ana.24040 · Cited by 222
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later
Roe, C. M., Fagan, A. M., Grant, E. A., Hassenstab, J., Moulder, K. L., Maue Dreyfus, D., Sutphen, C. L., Benzinger, T. L. S., Mintun, M. A., Holtzman, D. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182918ca6 · Cited by 222
Burnham, S. C., Bourgeat, P., Doré, V., Savage, G., Brown, B., Laws, S., Maruff, P., Salvado, O., Ames, D., Martins, R. N., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30125-9 · Cited by 207
Petersen, R. C., Wiste, H. J., Weigand, S. D., Rocca, W. A., Roberts, R. O., Mielke, M. M., Lowe, V. J., Knopman, D. S., Pankratz, V. S., Machulda, M. M., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3098 · Cited by 196
Self-citationATN classification and clinical progression in subjective cognitive decline: The SCIENCe project
Ebenau, J. L., Timmers, T., Wesselman, L. M. P., Verberk, I. M. W., Verfaillie, S. C. J., Slot, R. E. R., van Harten, A. C., Teunissen, C. E., Barkhof, F., van den Bosch, K. A., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009724 · Cited by 191
A second X chromosome contributes to resilience in a mouse model of Alzheimer’s disease
Davis, E. J., Broestl, L., Abdulai-Saiku, S., Worden, K., Bonham, L. W., Miñones-Moyano, E., Moreno, A. J., Wang, D., Chang, K., Williams, G., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz5677 · Cited by 176
Brookmeyer, R., & Abdalla, N. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.03.005 · Cited by 176
Qian, J., Wolters, F. J., Beiser, A., Haan, M., Ikram, M. A., Karlawish, J., Langbaum, J. B., Neuhaus, J. M., Reiman, E. M., Roberts, J. S., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002254 · Cited by 169 · cited 1×
“APOE ɛ4 increases the likelihood of and lowers the age of onset of both amyloidosis and dementia.(13,72,73)”
Association between male gender and cortical Lewy body pathology in large autopsy series
Nelson, P. T., Schmitt, F. A., Jicha, G. A., Kryscio, R. J., Abner, E. L., Smith, C. D., Van Eldik, L. J., & Markesbery, W. R. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5630-4 · Cited by 131
Stokes, A. C., Weiss, J., Lundberg, D. J., Xie, W., Kim, J. K., Preston, S. H., & Crimmins, E. M. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2831 · Cited by 94
Absolute 10-year risk of dementia by age, sex and APOE genotype: a population-based cohort study
Rasmussen, K. L., Tybjærg-Hansen, A., Nordestgaard, B. G., & Frikke-Schmidt, R. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.180066 · Cited by 91
Wolters, F. J., Yang, Q., Biggs, M. L., Jakobsdottir, J., Li, S., Evans, D. S., Bis, J. C., Harris, T. B., Vasan, R. S., Zilhao, N. R., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0219668 · Cited by 74
Knopman, D. S., Lundt, E. S., Therneau, T. M., Albertson, S. M., Gunter, J. L., Senjem, M. L., Schwarz, C. G., Mielke, M. M., Machulda, M. M., Boeve, B. F., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.3921 · Cited by 61
Self-citation
Cited by
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Self-citationOssenkoppele, R., Pichet Binette, A., Groot, C., Smith, R., Strandberg, O., Palmqvist, S., Stomrud, E., Tideman, P., Ohlsson, T., Jögi, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02049-x · Cited by 496
Self-citationAPOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease
Fortea, J., Pegueroles, J., Alcolea, D., Belbin, O., Dols-Icardo, O., Vaqué-Alcázar, L., Videla, L., Gispert, J. D., Suárez-Calvet, M., Johnson, S. C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02931-w · Cited by 369
Mattsson-Carlgren, N., Salvadó, G., Ashton, N. J., Tideman, P., Stomrud, E., Zetterberg, H., Ossenkoppele, R., Betthauser, T. J., Cody, K. A., Jonaitis, E. M., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2022.5272 · Cited by 309
Dubois, B., von Arnim, C. A. F., Burnie, N., Bozeat, S., & Cummings, J. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01314-6 · Cited by 288
Metadata
- Authors
- Jack, C. R., Therneau, T. M., Lundt, E. S., Wiste, H. J., Mielke, M. M., Knopman, D. S., Graff-Radford, J., Lowe, V. J., Vemuri, P., Schwarz, C. G., Senjem, M. L., Gunter, J. L., & Petersen, R. C.
- Venue
- Brain Communications
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-02-02
- Volume
- 4
- Issue
- 2
- Pages
- fcac017-fcac017
- ISSN
- 2632-1297 (ISSN-L)
- OpenAlex
- W4210382737
- Cited by
- 56
- References
- 44
- FWCI
- 6.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.